每经AI快讯，10月21日，泡泡玛特在港交所公告，2025年第三季度整体收益（未经审核）较2024第三 季度同比增长245%~250%，其中中国收益同比增长185%~190%，海外收益同比增长365%~370%。 （文章来源：每日经济新闻） ...

人民财讯10月21日电，泡泡玛特在港交所公告，2025年第三季度整体收益较2024年同期增长245%— 250%。其中，中国收益同比增长185%—190%，海外收益同比增长365%—370%。 ...

（文章来源：第一财经） 泡泡玛特在港交所公告，第三季度整体收益（未经审核），较二零二四年第三季度同比增长 245%-250%，其中中国收益同比增长185%-190%，海外收益同比增长365%-370%。 ...

Core Viewpoint - Pop Mart (09992.HK) announced that its overall revenue for Q3 2025 is expected to increase by 245%-250% year-on-year compared to Q3 2024, with significant growth in both domestic and overseas markets [1] Group 1: Revenue Growth - The overall revenue for Q3 2025 is projected to grow by 245%-250% year-on-year [1] - Domestic revenue in China is expected to increase by 185%-190% year-on-year [1] - Overseas revenue is anticipated to rise by 365%-370% year-on-year [1] Group 2: Channel Performance in China - Offline channel revenue in China is projected to grow by 130%-135% year-on-year [1] - Online channel revenue in China is expected to increase by 300%-305% year-on-year [1] Group 3: Regional Performance Overseas - Revenue in the Asia-Pacific region is expected to grow by 170%-175% year-on-year [1] - Revenue in the Americas is projected to increase by 1,265%-1,270% year-on-year [1] - Revenue in Europe and other regions is anticipated to rise by 735%-740% year-on-year [1]

市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何 意见、观点或结论是否符合其特定状况。据此投资，责任自负。 泡泡玛特公告，2025年第三季度整体收益较2024年同期增长245%-250%。其中，中国收益同比增长 185%-190%，海外收益同比增长365%-370%。 风险提示及免责条款 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 POP MART INTERNATIONAL GROUP LIMITED 泡泡瑪特國際集團有限公司 （於開曼群島註冊成立的有限公司） 二零二五年第三季度整體收益表現 二零二五年第三季度整體收益（未經審核），較二零二四年第三季度同比增長 245%-250%，其中中國收益同比增長185%-190%，海外1收益同比增長365%- 370%。 二零二五年第三季度中國各渠道收益表現 二零二五年第三季度中國各渠道收益（未經審核），與二零二四年第三季度比較 為： (1) 線下渠道同比增長130%-135%；及 （股份代號：9992） 二零二五年第三季度最新業務狀況 本公告由泡泡瑪特國際集團有限公司（「本公司」，連同其附屬公司及併表聯屬實 體統稱「本集團」）董事會（「董事會」）自願作出，以告知本公司股東及潛在投資者 本集團最新業務更新。 (2) 美洲同比增長1,265%-1,270%；及 (3) 歐洲及其他地區同比增長 ...

叶国富的潮玩梦离实现又近了一步。 近日，名创优品集团旗下潮玩品牌TOP TOY正式向港交所递交招股书，引发市场关注。 2021年初，叶国富在接受专访时曾激动的表示，"泡泡玛特这条路走对了，95后、00后追求精神层面，产品要有 情感投入。" 兴趣消费一直是叶国富最关注的，就算每天再忙，他都要刷一遍小红书，看看年轻人喜欢什么。而泡泡玛特深 受Z世代的追捧，让其羡慕不已，其一直想试图复制泡泡玛特的成功。 就在泡泡玛特上市当年，叶国富孵化出了潮玩品牌TOP TOY。 此前，其曾放话要让TOP TOY单独上市，如今终于迈出第一步。 历经5年沉淀，叶国富创办的TOP TOY已成为销售额仅次于泡泡玛特的国产潮玩品牌。数据显示，2024年，二者 市场份额分别为12.3%，2.2%。 然而，数字的背后，是两者之间依然悬殊的体量差距。 从业绩来看，2024年、2025年上半年，TOP TOY实现营收19.09亿元、13.60亿元，净利润2.94亿元、1.80亿元， 盈利能力仅为泡泡玛特的十分之一。 不过，叶国富打造的潮玩品牌更像是一款"名创优品版本"的泡泡玛特，不管是渠道、IP管理、运营模式，都难 逃"零售"标签。 因此，本次T ...

Investment Rating - The report maintains a "Strong Buy" investment rating for the company [4][8]. Core Insights - The company is expected to experience strong momentum from new product launches and continued rapid growth across various channels [8]. - The adjusted net profit for Q3 2025 is projected to be 30.3 billion yuan, reflecting a year-on-year growth of 198.6% [8]. - The company has introduced 31 new series of blind box figures and plush products in Q3 2025, with popular items selling out on the first day of launch [8]. - The number of retail stores in mainland China has increased to 513, a year-on-year growth of 6.4% [8]. - The company's online sales on platforms like Douyin and Tmall have shown significant growth, with Douyin's GMV reaching 1.31 billion yuan, up 302.2% year-on-year [8]. Financial Data and Valuation - Total revenue is projected to grow from 6.301 billion yuan in 2023 to 33.410 billion yuan in 2025, representing a compound annual growth rate (CAGR) of 156% [3][11]. - The adjusted net profit is expected to increase from 1.082 billion yuan in 2023 to 10.861 billion yuan in 2025, with a year-on-year growth rate of 248% [3][11]. - The adjusted PE ratio is forecasted to decrease from 326.1 in 2023 to 32.3 in 2025, indicating improved valuation metrics as earnings grow [3][12]. Key Financial Ratios - The gross profit margin is expected to improve from 61.3% in 2023 to 70.6% in 2025 [12]. - The net profit margin is projected to rise from 17.2% in 2023 to 32.5% in 2025 [12]. - Return on equity (ROE) is anticipated to increase significantly from 13.9% in 2023 to 51.3% in 2025 [12].

每经AI快讯，10月21日，港股消费股走弱，泡泡玛特跌超5%，古茗跌超4%，布鲁可、老铺黄金、蜜雪 集团等跟跌。 ...

Core Insights - I-Mab is transitioning to NovaBridge Biosciences, focusing on a global biotech innovation platform and plans to dual-list on the Hong Kong Stock Exchange and NASDAQ [1][2] - The company aims to bridge Chinese biotech innovations with global markets, enhancing the value of domestic innovations [2][7] - The "Hub-and-Spoke" model will be adopted, allowing for independent development of various product lines under a centralized management structure [3][4] Company Strategy - The new management team, led by CEO Dr. Fu Xiyong, is focused on recruiting talent to support the transformation and maximize the value of Chinese innovative drugs [2][5] - NovaBridge will leverage its parent company, Kangqiao Capital's resources, to support its global expansion and development strategy [4][6] - The company plans to target clinical-stage projects with high differentiation and competitive advantages, aiming for significant value increases during the clinical trial phases [9][10] Market Context - China has become a hotspot for biopharmaceutical innovation, with a significant increase in drug development activities since 2015, leading to a robust pipeline of innovative drugs [7][8] - The value of BD transactions in China's pharmaceutical sector has surged, with over $66.8 billion in overseas licensing agreements in the first half of 2025 [8] - The company aims to capture a larger share of the value chain, potentially increasing the returns from licensing agreements from 10% to as high as 50% [8][9] Competitive Landscape - NovaBridge's approach is compared to Roivant, but with a broader opportunity set in China, where numerous companies are engaged in drug development [10] - The efficiency and cost-effectiveness of conducting clinical trials in China provide a competitive advantage over Western markets [10] - The company plans to utilize both business development and self-commercialization strategies to maximize the value of its drug pipeline [10][11]